Our VB-600 program has also potential applications in chronic inflammatory conditions.
In 2017, we published novel data implicating MOSPD2, for the first time, in regulation of immune cell migration (Click here to view J Immunology paper)

Our research shows that knocking-out the MOSPD2 gene in mice could protect the animals from developing some inflammatory diseases. Moreover, we generated antibodies that can bind to MOSPD2 in a manner that shows major efficacy in a model of multiple sclerosis (unpublished data).

VBL is developing the VB-600 platform of biologic drug candidates for oncology and inflammatory indications.

For additional information you may listen to a webcast from our recent presentation at BIO 2018: BIO 2018 Webcast link